Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer

Shelley Dranko, Connie Kinney, Ramesh K. Ramanathan

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Cetuximab is a monoclonal antibody that specifically blocks the epidermal growth factor receptor pathway. Cetuximab is now a standard drug to treat refractory advanced colorectal cancer.The most common side effect is a rash, seen in most patients. Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed.

Original languageEnglish (US)
Pages (from-to)224-225
Number of pages2
JournalClinical colorectal cancer
Volume6
Issue number3
DOIs
StatePublished - Sep 2006

Keywords

  • Blepharitis
  • Epidermal growth factor receptor
  • Erythema
  • Itchiness
  • Tearing
  • Trichomegaly

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer'. Together they form a unique fingerprint.

  • Cite this